Homepage > Company > Media > Pharma News > 2024 > Johnson & Johnson acquires Ambrx Biopharma for $2bn

Johnson & Johnson acquires Ambrx Biopharma for $2bn

Integrating Ambrx's ADC technology into J&J's portfolio will aid in advancing the development of targeted oncology therapies. Johnson & Johnson (J&J) has concluded the acquisition of clinical-stage biopharmaceutical company Ambrx Biopharma in a $2bn transaction. The companies entered a definitive agreement to execute the acquisition in January 2024.

The acquisition will be deemed a business combination and marks a significant step for J&J in enhancing its oncology portfolio, particularly in the area of prostate cancer. The strategic move will also strengthen the company’s capabilities in developing next-generation antibody-drug conjugates (ADCs).

Ambrx’s synthetic biology technology platform is intended for designing and developing advanced ADCs. The integration of Ambrx’s ADC technology into J&J’s portfolio presents a unique opportunity to advance the development and commercialisation of targeted oncology therapies.

J&J will gain access to the Ambrx pipeline comprising candidate therapeutics for a range of cancer indications.

The assets comprise ARX517, an ADC for metastatic castration-resistant prostate cancer (mCRPC); ARX788, for treating human epidermal growth factor receptor 2 (HER2) for metastatic HER2+ breast cancer, and ARX305 to treat renal cell carcinoma.

J&J innovative medicine oncology global therapeutic area head Yusri Elsayed stated: “We’re pleased to welcome Ambrx’s talented scientific team and ADC platform to Johnson & Johnson. We look forward to continuing the development of ARX517, which represents a potential first and best-in-class PSMA [prostate-specific membrane antigen]-targeting ADC for the treatment of metastatic castration-resistant prostate cancer.”

The latest development comes after the US Food and Drug Administration granted full approval for J&J’s RYBREVANT (amivantamab-vmjw) plus chemotherapy for non-small cell lung cancer. This decision, which comes after a priority review, upgrades the May 2021 accelerated approval to full approval.

March 11, 2024

Read also

Phase 3 trials of treatment combo for hepatitis D expected in 2025

On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed ECLIPSE, to test its treatment combination of tobevibart and elebsi...

Breakthrough Therapy Designation Market Is Booming Worldwide 2024-2032

The Breakthrough Therapy Designation market has witnessed significant growth over the past decade, driven by advancements in technology, shifting consumer preferences, and increasing investments from ...

Veeva Commercial Summit: Increased investment in medical affairs by pharma companies

Veeva’s VP of global medical, Christoph Bug, emphasises the importance of scientific exchange between clinical experts and pharmaceutical companies.

Remix

Remix Therapeutics to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH)